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ABSTRACT Psoriasis is a chronic inflammatory disease, and its comorbidities 
have attracted serious interest in recent years. The evidence that psoriasis is 
associated with systemic inflammation and significantly higher incidence of 
cardiovascular risk factors has already been described. The results of published 
studies are highly variable, the conclusions are ambiguous, and further epi-
demiological studies are needed for validation of published data. Therefore, 
we initiated a project aimed at identifying the association with cardiovascular 
risk factors, including early stages of atherosclerosis, that represent impor-
tant comorbidities in patients with psoriasis. We carried out a hospital-based 
case-control study on 189 patients with chronic plaque psoriasis enrolled as 
cases. The control group consisted of 378 patients with other skin diseases 
complying with the same exclusion criteria who were recruited to the study 
as the controls. All participants underwent physical examination, blood tests, 
and measuring of blood pressure and waist circumference. Furthermore, we 
evaluated carotid intima-media thickness (CIMT) in a subset of 117 cases and 
controls (matched 1:2) with no history of cardiovascular disease. The results 
showed higher prevalence of hypertension, hyperlipidemia, waist circumfer-
ence, weight, body-mass index (BMI), and C-reactive protein (CRP) level in pa-
tients with psoriasis than in controls. These parameters have been clearly dem-
onstrated to be risk factors for the development of cardiovascular diseases. 
The associations between psoriasis and diastolic blood pressure, BMI value, 
and low-density lipoprotein (LDL) cholesterol were statistically significant in 
the binary data logistic model as well. CIMT was not significantly higher in pa-
tients compared with controls. 
KEY WORDS: psoriasis; cardiovascular comorbidities; atherosclerosis; risk fac-
tors; case-control study
INTRODUCTION
Psoriasis is a chronic inflammatory disease, pre-
dominantly affecting the skin, and is included in the 
group of immune mediated inflammatory diseases 
(1). Its prevalence ranges from around 1.5 % to 4.7% 
in Europe and in the USA. Some experimental and 
epidemiological studies have linked certain interleu-
kins, cytokines, and adipokines with cardiovascular 
disease, metabolic syndrome, obesity, and diabetes, 
making psoriasis a risk factor in developing system-
ic comorbidities (2-4). Inflammation also plays an 
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important role in the pathogenesis of atherosclerosis 
(5,6). There are therefore striking similarities between 
molecular and inflammatory pathways in psoriasis 
and atherosclerosis (7).
The presence of psoriasis in the past medical his-
tory of a patient is, therefore, considered to be one of 
the independent risk factors of atherosclerosis (8). 
In a recent published meta-analysis, the authors 
described that most of the studies reported a high 
prevalence of metabolic syndrome in patients with 
psoriasis, ranging from 14 to 40%, suggesting that 
metabolic syndrome is a common condition in pa-
tients with psoriasis (9).
In contrast to this statement, other authors found 
no association between severe psoriasis and obesity 
or between obesity and cardiovascular mortality in 
their studies (10). 
As associated comorbidities significantly impair 
the quality of life of patients suffering from psoriasis 
and contribute to increased morbidity and mortal-
ity of these patients (11,12), it is at present common 
practice to administer a number of screening tests 
that detect asymptomatic patients at risk of cardio-
vascular comorbidities and atherosclerosis, such as 
measurements of carotid artery intima media thick-
ness (13), basic blood tests (serum lipid levels, glyce-
mia), and physical examination. 
Based on the results of previous research and our 
own clinical experience, we designed a case-control 
study with the aim of contributing knowledge on the 
relationships described above. We tested the hypoth-
esis that the prevalence of cardiovascular risk factors 
and atherosclerosis is higher in patients with the 
chronic stationary form of psoriasis than in the con-
trol population.
PATIENTS AND METHODS
The study was designed as a hospital-based case-
control study, and 189 patients from Department of 
Dermatovenereology (Bulovka Hospital in Prague) 
with chronic plaque psoriasis were enrolled as cases. 
The control group consisted of 378 patients and was 
sampled at a 1:2 ratio from patients with other non-
autoimmune and non-acute infectious dermatologi-
cal and venereal diseases (e.g. patients with nevi in 
preventive care) according to the same exclusion cri-
teria applied for the case group. All the patients suf-
fering from chronic and autoimmune diseases, hyper-
tension, and diabetes mellitus as well as patients with 
centripetal obesity (men with waist circumference 
greater than 102 cm and women greater than 88 cm) 
were excluded from the study. Due to comparison be-
tween cases and controls in the asymptomatic stages 
of cardiovascular diseases, patients with apparent 
signs of tested risk factors or patients already treated 
for cardiovascular diseases were excluded as well.
Scope of medical examination
In each study patient we determined the follow-
ing parameters:
• age (all patients in study were 18-80 years old)
• sex
• waist circumference (cm)
•  weight (kg)
• height (m)
• body mass index (BMI)
• blood pressure (mmHg)
• glycemia (mmol/L)
Blood lipids:
• total cholesterol (mmol/L)
• low-density lipoprotein cholesterol (LDL) (mmol/L)
• high density lipoprotein cholesterol (HDL)  
    (mmol/L)
• triacylglycerol (TAG) (mmol/L)
• C-reactive protein (CRP) (mg/L)
The mean thickness of the right and left common 
carotid artery intima-media (IMT) were measured us-
ing color duplex ultrasound of the carotid arteries to 
compare carotid IMT values in a sample of partici-
pants (38 cases, 78 controls). 
Statistical analysis
Due to asymmetric distribution of most of the 
studied variables, the differences between cases and 
controls were tested by means of Mann-Whitney U 
test at the bivariate level. Simultaneous effects of 
the studied variables on the occurrences of psoriasis 
were studied by binary logistic regression. The point 
estimates of odds ratios and 95 % confidence interval 
(CI) describing the strength of association between 
independent predictors and occurrence of psoria-
sis are reported. Level of statistical significance in all 
tests was set to 0.05. 
RESULTS
Data on 189 cases and 378 controls are available. 
Differences in sex distribution did not reach the level 
of statistical significance. The main characteristics 
and the distribution of studied parameters are listed 
in the Table 1 and Table 2. Tests of statistically signifi-
cant differences between cases and controls are dis-
played in both tables. 
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The comparison of cases and controls revealed 
statistically significant differences in terms of several 
observed parameters (Table 1). Psoriasis cases had 
higher diastolic blood pressure than controls (Figure 
1), a bigger waist circumference, and a higher BMI 
value (Figure 2). The cases had higher LDL choles-
terol (Figure 3) as well. Using binary logistic regres-
sion, psoriasis was positively associated with diastolic 
blood pressure, BMI value, and LDL cholesterol (Table 
2). 
Table 1. Distributions of studied parameters and their comparison in cases and controls
Variable Status N Mean Median Minimum Maximum Std. Deviation Sig.
Age (years) Controls 378 40.07 36.00 16 94 15.50
0.047
 Cases 189 41.88 39.00 17 84 14.24
 Total 567 40.68 38.00 16 94 15.10  
Blood pressure 
systolic (mmHg)
Controls 378 120.73 120.00 90 170 13.61
0.000
Cases 188 126.52 130.00 95 180 15.00




Controls 377 78.06 80.00 50 118 9.14
0.000
Cases 188 83.08 80.00 60 120 11.46
Total 565 79.73 80.00 50 120 10.24  
Waist circumference (cm) Controls 378 83.16 82.50 58 117 11.81
0.000
 Cases 188 88.34 88.00 53 121 13.54
 Total 566 84.88 85.00 53 121 12.64  
Weight (kg) Controls 378 74.56 73.00 46 126 13.94
0.002
 Cases 188 79.58 78.00 45 152 17.76
 Total 566 76.23 74.00 45 152 15.48  
Height (m) Controls 378 1.74 1.75 1.38 2.00 0.10
0.381
 Cases 188 1.73 1.74 1.3 2.00 0.10
 Total 566 1.74 1.74 1.3 2.00 0.10  
BMI Controls 378 24.43 24.0 16.80 38.86 3.61
0.000
 Cases 188 26.32 26.11 17.76 47.34 4.63
 Total 566 25.6 24.62 16.80 47.34 4.7  
Total cholesterol (mmol/L) Controls 377 5.16 5.15 2.57 8.5 0.99
0.034
 Cases 186 5.37 5.35 2.23 9.52 1.10
 Total 563 5.23 5.18 2.23 9.52 1.3  
HDL (mmol/L) Controls 377 1.52 1.49 0.65 2.63 0.39
0.000
 Cases 186 1.4 1.35 0.78 3.1 0.34
 Total 563 1.48 1.43 0.65 3.1 0.38  
LDL (mmol/L) Controls 376 3.0 2.92 0.81 6.8 0.88
0.002
 Cases 186 3.23 3.11 1.00 5.97 0.91
 Total 562 3.5 2.99 0.81 6.8 0.90  
TAG (mmol/L) Controls 377 1.35 1.16 0.36 7.57 0.80
0.022
 Cases 186 1.53 1.3 0.45 5.76 0.94
 Total 563 1.41 1.2 0.36 7.57 0.85  
glycemia (mmol/L) Controls 377 4.83 4.8 2.6 9.4 0.73
0.901
 Cases 187 4.88 4.8 2.8 14.90 1,02
 Total 564 4.85 4.8 2.6 14.90 0.84  
CRP (mg/L) Controls 377 2.8 1.4 0.1 34.0 4.12
0.004
 Cases 186 3.71 1.95 0.2 71.1 6.50
 Total 563 3.1 1.5 0.1 71.1 5.4  
*HDL: high density lipoprotein; LDL: low-density lipoprotein; TAG: triacylglycerol; CRP: C-reactive protein
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DISCUSSION
The results of our study showed significant dif-
ferences between the case group and controls at the 
bivariate level in several studied parameters: blood 
pressure, waist circumference, weight, BMI, CRP, total 
cholesterol, HDL cholesterol, LDL cholesterol, and tri-
acylglycerols. The associations between psoriasis and 
diastolic blood pressure, BMI value, and LDL choles-
terol remain statistically significant in the binary data 
logistic model.
According to our results, psoriasis predisposes pa-
tients at least to hypertension, higher BMI values, and 
elevated levels of LDL cholesterol. These parameters 
belong to the clinical picture of metabolic syndrome 
and they are proven risk factors for the development 
of cardiovascular diseases on the basis of atheroscle-
rosis (myocardial infarction, stroke, and cardiovascu-
lar death) (14,15). 
We consider the finding of elevated levels of LDL 
cholesterol to be important because the association 
between psoriasis and this parameter is very robust, 
given the evidence from the multivariate model. Re-
sults of other studies are in accord with our findings 
regarding elevated total cholesterol levels in psoriasis 
(16-18) and raised LDL and very low density lipopro-
tein (VLDL) cholesterol among participants with pso-
riasis (16-20). Elevated baseline concentrations of CRP 
observed at the bivariate level of analysis are associ-
ated with an increased risk of atherosclerotic events 
and serve as a predictive parameter both in primary 
and secondary prevention (21). In the present study, 
the increased level of CRP in the case group was bor-
derline statistically significant (P=0.004). It can, there-
fore, be expected that if the case group grew suffi-
ciently, the difference in this parameter would reach 
a level of statistical significance.
BMI values as a sign of obesity in patients with 
psoriasis were increased and achieved significance 
both at binary as well as at multivariate levels of anal-
yses. The finding of higher BMI values correlated well 
with expectations and is consistent with previously 
published results (22,23).
Despite the expectations arising from the pub-
lished results of numerous studies (24-26), a higher 
level of glycemia was not seen in patients with pso-
riasis enrolled in our study compared to the control 
group. 
Regarding CIMT measurement, we did not find 
any statistically significant difference between cases 
and controls. This fact is in contrast with the majority 
of recent published studies – Balta et al. concluded 
that patients with psoriasis had a significantly greater 
CIMT compared with controls (27).
Figure1. Diastolic blood pressure in patients with psoriasis 
and controls (P<0.001).
Figure 2. Body mass index in patients with psoriasis and 
controls (P<0.001).
Figure 3. Low-density lipoprotein (LDL) cholesterol in pa-
tients with psoriasis and controls (P=0.002).
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Evensem et al., in accord with Balta et al., pub-
lished in 2014 that the results of their study support 
previous evidence. They suggest that psoriasis is as-
sociated with an increased risk of atherosclerosis and 
subsequent cardiovascular disease (28).
Discrepancy between our results and previous 
published studies may be due to the systemic treat-
ment of patients with psoriasis. In our study, 105 pa-
tients from the total number of 189 patients were 
treated with systemic agents. According to published 
results, the systemic treatment decreases the risk of 
atherosclerosis. The control group consists of patients 
(not of healthy population), so Bergson bias must be 
taken into account. The Bergson bias leads to distor-
tion towards zero as well, which is a consequence of 
the well-known fact that hospital controls are often 
people with a number of risk factors.
Contrary to the majority of published studies, our 
results are supported by an extensive Rotterdam study, 
which did not find any significant difference between 
cases and controls. A total of 262 psoriasis (24% system-
ic/UV treatment) and 8 009 reference subjects were fol-
lowed up for a mean of 11 years. The adjusted carotid 
intima-media thickness was 1.02±0.18 mm for psoriasis 
and 1.02±0.16 mm for reference subjects (29).
In the case of systolic and diastolic blood pressure, 
we found statistically significant differences. A statis-
tically significant difference in the case of diastolic 
blood pressure was also found in the binary logistic 
regression. These results are in accordance with the 
majority of published studies (30-31).
CONCLUSION 
The results of our study conducted on Czech pa-
tients with psoriasis suggest that detection of elevat-
ed or pathological values in several investigated pa-
rameters reaches the level of statistical significance.
Although no differences were found in the case 
of early stages of atherosclerosis and blood glucose, 
other modifiable risk factors such as hypertension, 
hyperlipidemia, elevated CRP, and centripetal obesity 
reached statistical significance. Our results are sup-
ported by the majority of published studies. Based 
on our findings, we suggest considering patients 
with psoriasis as an at-risk population for the devel-
opment of cardiovascular disease. Performing pre-
liminary diagnostics of concomitant diseases and re-
ferring the patient to an appropriate specialist should 
be the role of dermatologist. Primary prevention and 
early diagnostics of cardiovascular comorbidities 
benefit the health and quality of life of patients with 
psoriasis, but will also optimize available resources. 
Only a targeted individual approach to these patients 
can prevent their increased morbidity and mortality 
for cardiovascular diseases.
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